Clinical Trials Logo

Clinical Trial Summary

The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning >94% efficacy against COVID-19. However, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing), CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after a mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19. As such several countries including United States, Israel and Chile have recommended a third vaccine dose for this vulnerable population. In this observational study we will explore the humoral response to the BNT162b2 vaccine in patients who received two previous doses of the inactivated vaccine Coronavac or two doses of BNT162b2.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05119738
Study type Observational
Source Pontificia Universidad Catolica de Chile
Contact Bruno Nervi
Phone 9978073559
Email [email protected]
Status Recruiting
Phase
Start date October 27, 2021
Completion date January 1, 2022

See also
  Status Clinical Trial Phase
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Active, not recruiting NCT04593641 - This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) Phase 1
Recruiting NCT04602000 - To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19 Phase 2/Phase 3
Not yet recruiting NCT05017168 - To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects Phase 1
Recruiting NCT04516811 - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Phase 3
Not yet recruiting NCT05007275 - A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers Phase 1
Recruiting NCT05007236 - Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection. Phase 2
Recruiting NCT05012826 - Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID N/A
Suspended NCT04738136 - Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia Phase 2
Recruiting NCT04584658 - Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
Recruiting NCT04547114 - Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
Enrolling by invitation NCT05096962 - COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
Recruiting NCT04534400 - Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure
Completed NCT04527354 - Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia Phase 2
Completed NCT04583982 - ImmuneSense™ COVID-19 Study
Recruiting NCT05077176 - Phase 3 Booster Vaccination Against SARS-CoV-2 Phase 3
Recruiting NCT04600999 - Clinical Trial of Favipiravir Treatment of Patients With COVID-19 Phase 3
Terminated NCT04815018 - Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
Recruiting NCT05124509 - Immune Response to Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant
Not yet recruiting NCT05043311 - The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Adenovirus Vectored or mRNA COVID-19 Vaccine. Phase 2/Phase 3